Episodes

NCCN testing guidelines have long been a key tool that payers use to decide which cancer patients will be covered for genetic testing. With the rapid growth of precision medicine, it has become more important than ever to ensure every patient that should be tested is tested, raising new questions about how effectively and consistently current guidelines are applied. Dr. Peter Beitsch addresses some of those questions in a recent study published by the Journal of Clinical Oncology and many are sa...

NCCN testing guidelines have long been a key tool that payers use to decide which cancer patients will be covered for genetic testing. With the rapid growth of precision medicine, it has become more important than ever to ensure every patient that should be tested is tested, raising new questions about how effectively and consistently current guidelines are applied. Dr. Peter Beitsch addresses some of those questions in a recent study published by the Journal of Clinical Oncology and many are sa...

All of the conversations we have here at the Precision Medicine Podcast are focused on uncovering both barriers and solutions to realizing the promise of precision medicine. Having the opportunity to speak with Laura Holmes Haddad, an author, speaker, and breast cancer “thriver,” was especially meaningful, because it serves as a reminder that improving patient care—and giving every patient the best chance at beating cancer—is the ultimate goal. On this episode, Laura shares her experience with ...

All of the conversations we have here at the Precision Medicine Podcast are focused on uncovering both barriers and solutions to realizing the promise of precision medicine. Having the opportunity to speak with Laura Holmes Haddad, an author, speaker, and breast cancer “thriver,” was especially meaningful, because it serves as a reminder that improving patient care—and giving every patient the best chance at beating cancer—is the ultimate goal. On this episode, Laura shares her experience with ...

All of the conversations we have here at the Precision Medicine Podcast are focused on uncovering both barriers and solutions to realizing the promise of precision medicine. Having the opportunity to speak with Laura Holmes Haddad, an author, speaker, and breast cancer “thriver,” was especially meaningful, because it serves as a reminder that improving patient care—and giving every patient the best chance at beating cancer—is the ultimate goal. On this episode, Laura shares her experience with ...

Personalized medicine offers new hope for cancer patients, but those such a significant illness are not the only ones who can benefit from it. Dr. Keith Stewart joined us for an eye-opening discussion about how his team at the Mayo Clinic is exploring the possibilities of using precision medicine for the prevention and maintenance of a “healthy genome” in people who have not yet developed a disease. Listen in.

Personalized medicine offers new hope for cancer patients, but those such a significant illness are not the only ones who can benefit from it. Dr. Keith Stewart joined us for an eye-opening discussion about how his team at the Mayo Clinic is exploring the possibilities of using precision medicine for the prevention and maintenance of a “healthy genome” in people who have not yet developed a disease. Listen in.

Personalized medicine offers new hope for cancer patients, but those such a significant illness are not the only ones who can benefit from it. Dr. Keith Stewart joined us for an eye-opening discussion about how his team at the Mayo Clinic is exploring the possibilities of using precision medicine for the prevention and maintenance of a “healthy genome” in people who have not yet developed a disease. Listen in.

Diagnostics tests are critical for properly applying Precision Medicine in cancer care, yet they are still undervalued by payers. In a recent podcast, we had the privilege of speaking with Hannah Mamuszka, Ph.D. founder of Alva10, a company aimed at breaking the cycle of commoditization in diagnostics and bringing radically new tests to bear on value-based healthcare. Our conversation centered around the hurdles diagnostic companies face getting technology accepted and used for patients within ...

Diagnostics tests are critical for properly applying Precision Medicine in cancer care, yet they are still undervalued by payers. In a recent podcast, we had the privilege of speaking with Hannah Mamuszka, Ph.D. founder of Alva10, a company aimed at breaking the cycle of commoditization in diagnostics and bringing radically new tests to bear on value-based healthcare. Our conversation centered around the hurdles diagnostic companies face getting technology accepted and used for patients within ...

Diagnostics tests are critical for properly applying Precision Medicine in cancer care, yet they are still undervalued by payers. In a recent podcast, we had the privilege of speaking with Hannah Mamuszka, Ph.D. founder of Alva10, a company aimed at breaking the cycle of commoditization in diagnostics and bringing radically new tests to bear on value-based healthcare. Our conversation centered around the hurdles diagnostic companies face getting technology accepted and used for patients within ...

In oncology today, diagnostic technology tools are key to helping scientists unlock the potential of precision medicine, so we were thrilled when Dave Messina, Chief Operating Officer of Cofactor Genomics, agreed to be a guest on The Precision Medicine podcast to talk about the importance of such tools. <!-- /* Font Definitions */ @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-...

In oncology today, diagnostic technology tools are key to helping scientists unlock the potential of precision medicine, so we were thrilled when Dave Messina, Chief Operating Officer of Cofactor Genomics, agreed to be a guest on The Precision Medicine podcast to talk about the importance of such tools. <!-- /* Font Definitions */ @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-...

In oncology today, diagnostic technology tools are key to helping scientists unlock the potential of precision medicine, so we were thrilled when Dave Messina, Chief Operating Officer of Cofactor Genomics, agreed to be a guest on The Precision Medicine podcast to talk about the importance of such tools. <!-- /* Font Definitions */ @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-...

The impact of precision medicine is on everyone’s mind these days—especially those on the front lines of cancer care. So, it was an honor for to speak with, and get the perspective of, one of the most vocal and forward-thinking pathologists in oncology today: Doctor Tony Magliocco, Chair of the Department of Pathology and Executive Director of Esoteric Laboratory Services at H. Lee Moffitt Cancer Center in Tampa, Florida.

The impact of precision medicine is on everyone’s mind these days—especially those on the front lines of cancer care. So, it was an honor for to speak with, and get the perspective of, one of the most vocal and forward-thinking pathologists in oncology today: Doctor Tony Magliocco, Chair of the Department of Pathology and Executive Director of Esoteric Laboratory Services at H. Lee Moffitt Cancer Center in Tampa, Florida.

The impact of precision medicine is on everyone’s mind these days—especially those on the front lines of cancer care. So, it was an honor for to speak with, and get the perspective of, one of the most vocal and forward-thinking pathologists in oncology today: Doctor Tony Magliocco, Chair of the Department of Pathology and Executive Director of Esoteric Laboratory Services at H. Lee Moffitt Cancer Center in Tampa, Florida.